Total Funding
55
27
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
56979
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Acquired by 
Novo Nordisk
- Tim Rolph: CSO & Co-Founder
- Jonathan Young: President, CEO & Co-FounderPast Role: Braeburn, General Counsel & VP Policy
About the Company
Akero Therapeutics is a biopharmaceutical company focused on developing therapies for patients with serious metabolic diseases. The company’s pipeline centers on the development of Efruxifermin (EFX) for the treatment of pre-cirrhotic MASH, formerly known as NASH. Akero Therapeutics conducts clinical trials and research programs related to its
therapeutic focus.
